Table 1 Characteristics of completed versus discontinued trials and published versus unpublished trials (n = 130)
From: Discontinuation and nonpublication of clinical trials in orthopaedic oncology
Characteristic | Total (n = 130) | Trial status | Publication status | ||||
|---|---|---|---|---|---|---|---|
Discontinued (25) | Completed (105) | χ2, P | Published (112) | Unpublished (18) | χ2, P | ||
Intervention | |||||||
 Pharmaceutical | 111 (85.4%) | 23 (92.0%) | 88 (83.8%) | Pearson χ2 = 5.98, P < .001 | 103 (91.96%) | 8 (44%) | Pearson χ2 = .99, P = .008 |
 Behavioral/dietary | 7 (5.4%) | 0 (0%) | 7 (5.38%) | 3 (2.68%) | 4 (22%) | ||
 Device | 2 (1.5%) | 1 (4.0%) | 1 (1.0%) | 0 (0%) | 2 (11.1%) | ||
 Procedure | 10 (7.7%) | 1 (4.0%) | 9 (8.6%) | 6 (5.35%) | 4 (22%) | ||
Funding | |||||||
 NIH | 50 (38.5%) | 10 (40.0%) | 40 (38.5%) | Pearson χ2 = .8286, P = .17 | 46 (41.1%) | 4 (19.05%) | Pearson χ2 = 0.3318, P = .67 |
 Industry | 72 (55.4%) | 13 (52.0%) | 59 (56.19%) | 64 (54.46%) | 8 (52.38%) | ||
 Mixed | 2 (1.5%) | 0 (0%) | 2 (1.9%) | 0 (0%) | 2 (9.52%) | ||
 Other | 6 (4.6%) | 2 (8.0%) | 4 (3.8%) | 2 (1.8%) | 4 (19.05%) | ||
Published | |||||||
 No | 18 (13.8%) | 4 (16%) | 14 (13.3%) | Pearson χ2 = 23.64, P < .001 | 0 (0%) | 18 (100%) | – |
 Yes | 112 (86.2%) | 21 (84%) | 91 (86.7%) | 112 (100%) | 0 (0%) | ||
Completed | |||||||
 No | 25 (19.2%) | 25 (100%) | 0 (0%) | – | 19 (16.96%) | 6 (33.3%) | Pearson χ2 = 9.05, P < .001 |
 Yes | 105 (80.8%) | 0 (0%) | 105 (100%) | 93 (83.03%) | 12 (66.7%) | ||
Enrollment; median: 261 (IQR: 72–615) | |||||||
 < 261 | 59 (45.4%) | 17 (68.0%) | 42 (40.0%) | Pearson χ2 = 8.72, P < .001 | 51 (45.5%) | 8 (44.4%) | Pearson χ2 = 7.69, P < .001 |
 ≥ 261 | 71 (54.6%) | 8 (32.0%) | 63 (60.0%) | 61 (54.5%) | 10 (55.6%) | ||